<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28542447</article-id><article-id pub-id-type="pmc">5444835</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0178444</article-id><article-id pub-id-type="publisher-id">PONE-D-16-42546</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Colorectal Cancer</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Plasma Proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Signal Transduction</subject><subj-group><subject>Cell Signaling</subject><subj-group><subject>Membrane Receptor Signaling</subject><subj-group><subject>Hormone Receptor Signaling</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteomics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Analgesics</subject><subj-group><subject>NSAIDs</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pain management</subject><subj-group><subject>Analgesics</subject><subj-group><subject>NSAIDs</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>DNA-binding proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Bioenergetics</subject><subj-group><subject>Energy-Producing Organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Structures and Organelles</subject><subj-group><subject>Energy-Producing Organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Exploratory plasma proteomic analysis in a randomized crossover trial of aspirin among healthy men and women</article-title><alt-title alt-title-type="running-head">Proteomic analysis of aspirin trial</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5184-2935</contrib-id><name><surname>Wang</surname><given-names>Xiaoliang</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Shojaie</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yuzheng</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shelley</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lampe</surname><given-names>Paul D.</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Levy</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peters</surname><given-names>Ulrike</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Potter</surname><given-names>John D.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lampe</surname><given-names>Johanna W.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Epidemiology, University of Washington, Seattle, Washington, United States of America</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Department of Biostatistics, University of Washington, Seattle, Washington, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Zhang</surname><given-names>Hong-Liang</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>National Natural Science Foundation of China, CHINA</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> XW JP EW JL.</p></list-item><list-item><p><bold>Data curation:</bold> XW YZ DS PL LL.</p></list-item><list-item><p><bold>Formal analysis:</bold> XW AS YZ.</p></list-item><list-item><p><bold>Funding acquisition:</bold> JP EW JL.</p></list-item><list-item><p><bold>Investigation:</bold> DS PL LL JL.</p></list-item><list-item><p><bold>Methodology:</bold> XW AS YZ.</p></list-item><list-item><p><bold>Project administration:</bold> LL.</p></list-item><list-item><p><bold>Resources:</bold> DS LL.</p></list-item><list-item><p><bold>Software:</bold> XW AS YZ.</p></list-item><list-item><p><bold>Supervision:</bold> PL EW JL UP.</p></list-item><list-item><p><bold>Validation:</bold> XW YZ.</p></list-item><list-item><p><bold>Visualization:</bold> XW.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> XW.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> XW AS YZ PL LL UP JP EW JL.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>xwang23@fredhutch.org</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>5</issue><elocation-id>e0178444</elocation-id><history><date date-type="received"><day>25</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Wang et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Wang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0178444.pdf"/><abstract><p>Long-term use of aspirin is associated with lower risk of colorectal cancer and other cancers; however, the mechanism of chemopreventive effect of aspirin is not fully understood. Animal studies suggest that COX-2, NF&#x003ba;B signaling and Wnt/&#x003b2;-catenin pathways may play a role, but no clinical trials have systematically evaluated the biological response to aspirin in healthy humans. Using a high-density antibody array, we assessed the difference in plasma protein levels after 60 days of regular dose aspirin (325 mg/day) compared to placebo in a randomized double-blinded crossover trial of 44 healthy non-smoking men and women, aged 21&#x02013;45 years. The plasma proteome was analyzed on an antibody microarray with ~3,300 full-length antibodies, printed in triplicate. Moderated paired t-tests were performed on individual antibodies, and gene-set analyses were performed based on KEGG and GO pathways. Among the 3,000 antibodies analyzed, statistically significant differences in plasma protein levels were observed for nine antibodies after adjusting for false discoveries (FDR adjusted p-value&#x0003c;0.1). The most significant protein was succinate dehydrogenase subunit C (SDHC), a key enzyme complex of the mitochondrial tricarboxylic acid (TCA) cycle. The other statistically significant proteins (NR2F1, MSI1, MYH1, FOXO1, KHDRBS3, NFKBIE, LYZ and IKZF1) are involved in multiple pathways, including DNA base-pair repair, inflammation and oncogenic pathways. None of the 258 KEGG and 1,139 GO pathways was found to be statistically significant after FDR adjustment. This study suggests several chemopreventive mechanisms of aspirin in humans, which have previously been reported to play a role in anti- or pro-carcinogenesis in cell systems; however, larger, confirmatory studies are needed.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R25 CA094880</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5184-2935</contrib-id><name><surname>Wang</surname><given-names>Xiaoliang</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R25 CA094880</award-id><principal-award-recipient><name><surname>White</surname><given-names>Emily</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>K05 CA154337</award-id><principal-award-recipient><name><surname>White</surname><given-names>Emily</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 CA094954</award-id><principal-award-recipient><name><surname>Lampe</surname><given-names>Johanna W.</given-names></name></principal-award-recipient></award-group><funding-statement>X. Wang received financial support from the National Institutes of Health grant R25 CA094880 (National Cancer Institute); E. White received financial support from the National Institutes of Health grant K05 CA154337 (National Cancer Institute and Office of Dietary Supplements); J. Lampe received financial support from the National Institutes of Health grant R01 CA094954. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="12"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Low-dose and regular-strength aspirin use is consistently observed to be associated with reduced long-term risk of colorectal cancer (CRC) risk of adenomatous polyps, pre-cancerous lesions that increase risk of CRC [<xref rid="pone.0178444.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0178444.ref002" ref-type="bibr">2</xref>]. Benefit increases with duration of aspirin use and is associated with 34% reduction in 20-year CRC risk [<xref rid="pone.0178444.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0178444.ref003" ref-type="bibr">3</xref>]. Evidence consistently suggests that aspirin plays a role at an early stage or even before tumorigenesis [<xref rid="pone.0178444.ref004" ref-type="bibr">4</xref>]. Therefore, studies of aspirin involving healthy individuals may help elucidate biological responses related to the chemopreventive effects of aspirin.</p><p>The presumed main mechanism by which aspirin lowers adenomatous polyps and CRC risk is by reducing inflammatory mediators through the inhibition of cyclooxygenase-2 (COX-2) activity [<xref rid="pone.0178444.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0178444.ref006" ref-type="bibr">6</xref>] and subsequent formation of prostaglandin E2 (PGE2) [<xref rid="pone.0178444.ref007" ref-type="bibr">7</xref>]. Aspirin has also been shown to inhibit the oncogenic Wnt/&#x003b2;-catenin pathway [<xref rid="pone.0178444.ref008" ref-type="bibr">8</xref>] and the extracellular-signal-regulated kinase (ERK) signaling pathway [<xref rid="pone.0178444.ref009" ref-type="bibr">9</xref>] in colon cancer cell lines. Indirect support for these pathways from human studies comes from nested case-control studies which suggest that interactions between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and polymorphisms in oncogenes in the Wnt/&#x003b2;-catenin signaling pathway [<xref rid="pone.0178444.ref010" ref-type="bibr">10</xref>] and NF&#x0043a;B-signaling pathway [<xref rid="pone.0178444.ref011" ref-type="bibr">11</xref>] modify CRC risk [<xref rid="pone.0178444.ref012" ref-type="bibr">12</xref>]. Recently, a genome-wide investigation of gene-environment interactions reported that the association of NSAIDs with CRC risk differed according to genetic variation at 2 SNPs [<xref rid="pone.0178444.ref013" ref-type="bibr">13</xref>]; these are related to genes involved in activation of the PI3K signaling pathway. Other pathways related to transcription factors, cell proliferation and apoptosis have also been suggested [<xref rid="pone.0178444.ref014" ref-type="bibr">14</xref>].</p><p>No human intervention trials have yet systematically explored proteomic profiling of aspirin use among human subjects. A randomized controlled trial of diclofenac among overweight individuals identified a group of inflammation-related modulators [<xref rid="pone.0178444.ref015" ref-type="bibr">15</xref>]; another trial suggested a variety of pathways, including cytokine activity pathways, in response to glucosamine and chondroitin supplementation [<xref rid="pone.0178444.ref016" ref-type="bibr">16</xref>]. These studies support the utility of proteomic profiling in characterizing responses to drugs or supplements with pleiotropic effects. We created a high density antibody array containing &#x0003e;3,200 different antibodies to ~2,100 different proteins that we use to interrogate plasma or other biological samples for cellular activation status including proteins involved in apoptosis, proliferation, angiogenesis, immune cell activity/infiltration, and metabolism, etc. Many of the antibodies are to secreted proteins such as cytokines and growth factors including 21 proteins with insulin in their names. We have used these arrays to find biomarkers of ovarian [<xref rid="pone.0178444.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0178444.ref018" ref-type="bibr">18</xref>], breast [<xref rid="pone.0178444.ref019" ref-type="bibr">19</xref>], pancreas [<xref rid="pone.0178444.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0178444.ref021" ref-type="bibr">21</xref>] and colon [<xref rid="pone.0178444.ref022" ref-type="bibr">22</xref>] cancer and used the values derived to find pathways important in obesity [<xref rid="pone.0178444.ref023" ref-type="bibr">23</xref>], supplement usage [<xref rid="pone.0178444.ref016" ref-type="bibr">16</xref>], anti-apoptotic cell survival signaling pathways [<xref rid="pone.0178444.ref022" ref-type="bibr">22</xref>], and incisional hernia [<xref rid="pone.0178444.ref024" ref-type="bibr">24</xref>]. The objective of this study was to explore potential mechanisms relevant to the effects of aspirin through proteomic analysis in healthy participants in a randomized trial of aspirin, with a focus on proteins that are related to cancer development.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Study design</title><p>The Aspirin and the Biology of the Colon (ABC) study was a randomized, double-blinded, placebo-controlled, crossover trial [<xref rid="pone.0178444.ref025" ref-type="bibr">25</xref>]. During each intervention period, participants took 325 mg aspirin or a visually identical placebo orally each day for 60 days, with a 3-month washout period between the treatment periods. Study activities, including participant interviews and blood draws, were conducted at the Fred Hutchinson Cancer Research Center (Fred Hutch) Prevention Center Research Clinic. The study procedures were approved by the Fred Hutch Institutional Review Board; informed, written consent was obtained from all participants prior to participation in the study.</p></sec><sec id="sec004"><title>Study participants</title><p>Details of the study and the study population have been described previously [<xref rid="pone.0178444.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0178444.ref026" ref-type="bibr">26</xref>] and are summarized in <xref ref-type="supplementary-material" rid="pone.0178444.s003">S1 Fig</xref>. Briefly, healthy men and women, aged 21 to 45 years, were recruited from participants from the greater Seattle area who completed a cross-sectional study of diet and aspirin metabolism between June 2003 and March 2007 [<xref rid="pone.0178444.ref027" ref-type="bibr">27</xref>]. Individuals were excluded if they had: a medical history of gastrointestinal, hepatic, or renal disorders; family history of familial adenomatous polyposis or Lynch syndrome; known intolerance to aspirin or other NSAIDs; weight change greater than 4.5 kg within the past year; current use of prescription medication (including oral contraceptives) or over-the-counter medications; alcohol intake &#x0003e;2 drinks/day; were pregnant or lactating; or were planning to move out of the greater Seattle area within the 12 months of the study period. Given that an aim of the parent study was to determine whether genetic variation in <italic>UGT1A6</italic> influenced response to aspirin [<xref rid="pone.0178444.ref025" ref-type="bibr">25</xref>], participants who met these criteria were further selected based on <italic>UGT1A6</italic> genotypes (rs2070959 and rs1105879) so that all subjects with a <italic>*2/*2</italic> genotype and sex-matched participants with a <italic>*1/*1</italic> genotype were invited to participate. Additionally, two participants with a <italic>*2/*4</italic> genotype were also included and randomized. Clinical measurements were also assessed and participants with abnormal laboratory values were excluded from participation. A total of 55 healthy men and women were recruited into the trial, randomly assigned, blocked on sex and <italic>UGT1A6</italic> genotype, to the order of receiving aspirin or placebo. Forty-four participants completed both intervention periods. The reasons participants dropped out were not related to either intervention or placebo period.</p></sec><sec id="sec005"><title>Data collection</title><p>Demographics and medical history were obtained through questionnaires at the time of recruitment, including age, ethnicity, previous smoking habits, dietary supplement use, alcohol intake, history of weight change, and general health. Twelve-hour fasting morning blood samples were drawn on day -5 and day 55 of the first intervention period, and days 1 and 55 of the second intervention period. The pre-intervention blood samples were tested for liver and kidney function, and post-intervention blood samples were used for research purposes. Blood samples were collected in EDTA-containing vacutainer tubes; plasma was aliquoted into cryovials and stored at -80&#x000b0;C until analysis.</p></sec><sec id="sec006"><title>Proteomics analyses</title><p>Plasma samples were analyzed on a customized antibody array populated with ~3,300 full-length antibodies, printed in triplicate on a single microarray according to published methods [<xref rid="pone.0178444.ref020" ref-type="bibr">20</xref>&#x02013;<xref rid="pone.0178444.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0178444.ref028" ref-type="bibr">28</xref>]. Briefly, each sample (200 &#x003bc;g) was combined with the same amount of a Cy3 labeled &#x0201c;reference&#x0201d; pool (from 5 healthy men and 5 women) of albumin and IgG-depleted plasma, placed on the array and Cy3 and Cy5 signals determined. The log2-transformed Cy5/Cy3 ratio, noted as M value, determined the relative concentration of protein compared to reference. For quality-control purposes, triplicate antibodies with coefficients of variation &#x0003e;10% were removed, and experimental variation was normalized using within-array print-tip loess normalization and between-array quartile normalization [<xref rid="pone.0178444.ref029" ref-type="bibr">29</xref>]. The median for each antibody was taken from triplicates as the summary measure.</p><p>The two samples from the same person collected at the termination of the two periods (aspirin and placebo) were analyzed in the same batch with the order of treatment periods randomized. Sex and genotypes were randomly distributed across batches. Additional possible batch effects were checked by principal component analysis (data not shown).</p><p>Previous analyses showed that coefficients of variation, for triplicates, for &#x0003e;85% antibodies on the array were less than 10% [<xref rid="pone.0178444.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0178444.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0178444.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0178444.ref031" ref-type="bibr">31</xref>]. Intra-class correlation (R<sub>1</sub>) for triplicates was also used to evaluate the reliability of triplicates in this study [<xref rid="pone.0178444.ref032" ref-type="bibr">32</xref>]. 92.5% of the antibodies had at least moderate correlation among triplicates (R<sub>1</sub>&#x0003e;0.5), and 83.5% antibodies had strong correlations among triplicates (R<sub>1</sub>&#x0003e;0.7), suggesting reliable measurements of plasma protein levels. Antibodies were also highly correlated between quality-control duplicate samples that were blinded to the lab analysist.</p></sec><sec id="sec007"><title>Statistical analysis</title><p>Antibodies with more than 30% missing values across the arrays were excluded from further analysis. Remaining missing data were imputed using the local least squares imputation method, which replaces a target protein that has missing values with a linear combination of 10 similar proteins, chosen by k-nearest neighbors based on Pearson correlation coefficients [<xref rid="pone.0178444.ref033" ref-type="bibr">33</xref>]. Of ~3,300 antibodies on the array, 3,000 proteins were available for statistical analyses and complete data were available on all 44 participants after imputation. Moderated paired t-tests [<xref rid="pone.0178444.ref034" ref-type="bibr">34</xref>] were performed for individual proteins to determine statistically significant differences between aspirin and placebo treatments. Adjustment for potential confounders, including batch effect, sample positions, and covariate effects of sex and <italic>UGT1A6</italic> genotype was carried out using a mixed linear regression model. The proteins were then ranked on the basis of p-values adjusted by Benjamini-Hochberg false discovery rate (FDR) correction, at a significance level of 0.1 [<xref rid="pone.0178444.ref034" ref-type="bibr">34</xref>]. Both the moderated t-tests and FDR corrections were performed using the R LIMMA package [<xref rid="pone.0178444.ref029" ref-type="bibr">29</xref>].</p><p>Pathway analyses were also carried out [<xref rid="pone.0178444.ref035" ref-type="bibr">35</xref>], using gene sets in Kyoto Encyclopedia of Genes and Genomes (KEGG) and the Gene Ontology (GO). KEGG gene sets were obtained via REST server to KEGG, and GO gene sets were obtained from MSigDB (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea/msigdb/index.jsp">http://www.broadinstitute.org/gsea/msigdb/index.jsp</ext-link>). Simulation analyses were performed to compare several gene-set analytical tools [<xref rid="pone.0178444.ref035" ref-type="bibr">35</xref>&#x02013;<xref rid="pone.0178444.ref037" ref-type="bibr">37</xref>]. The Significance Analysis of Functional Categories (SAFE) framework [<xref rid="pone.0178444.ref035" ref-type="bibr">35</xref>] outperformed the other methods in relation to sensitivity and specificity, and was used in further analysis. Gene sets with fewer than 3 genes were excluded from the analysis. The enriched gene sets were ranked on the basis of adjusted p-values, with an FDR significance level of 0.1.</p></sec></sec><sec sec-type="results" id="sec008"><title>Results</title><p>The demographic characteristics of the 44 study participants are summarized in <xref ref-type="table" rid="pone.0178444.t001">Table 1</xref>. The study population was predominantly Caucasian, and approximately half of the participants were overweight or obese (BMI&#x02265;25 kg/m<sup>2</sup>).</p><table-wrap id="pone.0178444.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178444.t001</object-id><label>Table 1</label><caption><title>Demographic characteristics of 44 participants.</title></caption><alternatives><graphic id="pone.0178444.t001g" xlink:href="pone.0178444.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">Characteristics</th><th align="justify" rowspan="1" colspan="1">N (%)</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">Age, Mean(SD)</td><td align="justify" rowspan="1" colspan="1">30.43 (5.97)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Sex</td><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Male</td><td align="justify" rowspan="1" colspan="1">20 (45.5)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Female</td><td align="justify" rowspan="1" colspan="1">24 (54.5)</td></tr><tr><td align="justify" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Normal (&#x0003c;25)</td><td align="justify" rowspan="1" colspan="1">23 (52.3)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Overweight or obese (&#x02265;25)</td><td align="justify" rowspan="1" colspan="1">21 (47.7)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Race/Ethnicity</td><td align="justify" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Caucasian</td><td align="justify" rowspan="1" colspan="1">33 (75.0)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;African-American</td><td align="justify" rowspan="1" colspan="1">1 (2.3)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Asian</td><td align="justify" rowspan="1" colspan="1">5 (11.4)</td></tr><tr><td align="justify" rowspan="1" colspan="1">&#x02003;Other</td><td align="justify" rowspan="1" colspan="1">5 (11.4)</td></tr></tbody></table></alternatives></table-wrap><p>Among the 3,000 proteins tested, nine were statistically different between the aspirin and placebo periods after FDR correction (adjusted p-value&#x0003c;0.1) (<xref ref-type="table" rid="pone.0178444.t002">Table 2</xref>), including energy convertors, hormone receptors, transcriptional factors, and RNA- and DNA-binding proteins. Among these nine proteins, six (MYH1, FOXO1, KHDRBS3, NFKBIE, LYZ and IKZF1) had a higher expression level on aspirin than placebo, whereas the other three (SDHC, NR2F1 and MSI1) had a lower expression level on aspirin than placebo. The most significant protein was succinate dehydrogenase subunit C (SDHC), with an average 34% lower expression level on aspirin than placebo (p-value = 4.47&#x000d7;10<sup>&#x02212;05</sup>; FDR-adjusted p-value = 0.06). The next most significant was myosin-1 (MYH1). The expression level of MYH1 on aspirin treatment was 62% higher on average than that on placebo (p-value = 6.83&#x000d7;10<sup>&#x02212;05</sup>; FDR-adjusted p-value = 0.06). The largest decrease was observed in a nuclear hormone receptor NR2F1 with 60% lower expression level on aspirin than placebo. NF-&#x003ba;B inhibitor epsilon (NFKBIE) had one of the largest increases: the expression level was 63% higher on aspirin than placebo. Because the study was conducted as a randomized crossover study, each participant served as their own control; predictably, adjusting for batch effects, sample positions, order of aspirin and placebo period, and other covariates did not change test results.</p><table-wrap id="pone.0178444.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178444.t002</object-id><label>Table 2</label><caption><title>Proteins that differed significantly between aspirin and placebo periods with false discovery rate (FDR) &#x0003c;0.10.</title></caption><alternatives><graphic id="pone.0178444.t002g" xlink:href="pone.0178444.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="2" colspan="1">Symbol</th><th align="center" rowspan="2" colspan="1">Function<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref></th><th align="center" rowspan="2" colspan="1">Missing%<xref ref-type="table-fn" rid="t002fn002"><sup>b</sup></xref></th><th align="center" colspan="2" rowspan="1">Average expression<xref ref-type="table-fn" rid="t002fn003"><sup>c</sup></xref></th><th align="center" rowspan="2" colspan="1">Effect size<xref ref-type="table-fn" rid="t002fn004"><sup>d</sup></xref></th><th align="center" rowspan="2" colspan="1">Fold change<xref ref-type="table-fn" rid="t002fn005"><sup>e</sup></xref></th><th align="center" rowspan="2" colspan="1">p-value<xref ref-type="table-fn" rid="t002fn006"><sup>f</sup></xref></th><th align="center" rowspan="2" colspan="1">Adjusted p-value<xref ref-type="table-fn" rid="t002fn007"><sup>g</sup></xref></th></tr><tr><th align="center" rowspan="1" colspan="1">aspirin</th><th align="center" rowspan="1" colspan="1">placebo</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">SDHC</td><td align="left" rowspan="1" colspan="1">Conservative effector of mitochondrial Krebs cycle and respiratory chain</td><td align="char" char="." rowspan="1" colspan="1">20.5</td><td align="char" char="." rowspan="1" colspan="1">-0.259</td><td align="char" char="." rowspan="1" colspan="1">-0.112</td><td align="char" char="." rowspan="1" colspan="1">-0.594</td><td align="char" char="." rowspan="1" colspan="1">0.662</td><td align="center" rowspan="1" colspan="1">4.47&#x000d7;10<sup>&#x02212;05</sup></td><td align="char" char="." rowspan="1" colspan="1">0.058</td></tr><tr><td align="justify" rowspan="1" colspan="1">MYH1</td><td align="left" rowspan="1" colspan="1">Energy convertor in base excision repair (BER) pathway</td><td align="char" char="." rowspan="1" colspan="1">18.2</td><td align="char" char="." rowspan="1" colspan="1">-0.262</td><td align="char" char="." rowspan="1" colspan="1">-0.454</td><td align="char" char="." rowspan="1" colspan="1">0.698</td><td align="char" char="." rowspan="1" colspan="1">1.622</td><td align="center" rowspan="1" colspan="1">6.83&#x000d7;10<sup>&#x02212;05</sup></td><td align="char" char="." rowspan="1" colspan="1">0.058</td></tr><tr><td align="justify" rowspan="1" colspan="1">NR2F1</td><td align="left" rowspan="1" colspan="1">Nuclear hormone receptor and transcriptional regulator</td><td align="char" char="." rowspan="1" colspan="1">11.4</td><td align="char" char="." rowspan="1" colspan="1">-0.371</td><td align="char" char="." rowspan="1" colspan="1">-0.265</td><td align="char" char="." rowspan="1" colspan="1">-0.755</td><td align="char" char="." rowspan="1" colspan="1">0.592</td><td align="center" rowspan="1" colspan="1">6.94&#x000d7;10<sup>&#x02212;05</sup></td><td align="char" char="." rowspan="1" colspan="1">0.058</td></tr><tr><td align="justify" rowspan="1" colspan="1">FOXO1</td><td align="left" rowspan="1" colspan="1">Transcription factor in carbohydrates metabolism and Akt-mTOR signaling pathway</td><td align="char" char="." rowspan="1" colspan="1">17.0</td><td align="char" char="." rowspan="1" colspan="1">1.003</td><td align="char" char="." rowspan="1" colspan="1">0.845</td><td align="char" char="." rowspan="1" colspan="1">0.520</td><td align="char" char="." rowspan="1" colspan="1">1.434</td><td align="center" rowspan="1" colspan="1">7.72&#x000d7;10<sup>&#x02212;05</sup></td><td align="char" char="." rowspan="1" colspan="1">0.058</td></tr><tr><td align="justify" rowspan="1" colspan="1">KHDRBS3</td><td align="left" rowspan="1" colspan="1">RNA-binding protein regulating pre-mRNA splicing, signaling and cell cycle control</td><td align="char" char="." rowspan="1" colspan="1">27.3</td><td align="char" char="." rowspan="1" colspan="1">0.096</td><td align="char" char="." rowspan="1" colspan="1">-0.028</td><td align="char" char="." rowspan="1" colspan="1">0.400</td><td align="char" char="." rowspan="1" colspan="1">1.320</td><td align="center" rowspan="1" colspan="1">2.07&#x000d7;10<sup>&#x02212;04</sup></td><td align="char" char="." rowspan="1" colspan="1">0.087</td></tr><tr><td align="justify" rowspan="1" colspan="1">NFKBIE</td><td align="left" rowspan="1" colspan="1">NF-&#x003ba;B inhibitor epsilon</td><td align="char" char="." rowspan="1" colspan="1">23.9</td><td align="char" char="." rowspan="1" colspan="1">0.530</td><td align="char" char="." rowspan="1" colspan="1">0.374</td><td align="char" char="." rowspan="1" colspan="1">0.709</td><td align="char" char="." rowspan="1" colspan="1">1.634</td><td align="center" rowspan="1" colspan="1">2.15&#x000d7;10<sup>&#x02212;04</sup></td><td align="char" char="." rowspan="1" colspan="1">0.087</td></tr><tr><td align="justify" rowspan="1" colspan="1">LYZ</td><td align="left" rowspan="1" colspan="1">Lysozyme, antimicrobial enzyme</td><td align="char" char="." rowspan="1" colspan="1">26.1</td><td align="char" char="." rowspan="1" colspan="1">0.004</td><td align="char" char="." rowspan="1" colspan="1">-0.147</td><td align="char" char="." rowspan="1" colspan="1">0.689</td><td align="char" char="." rowspan="1" colspan="1">1.612</td><td align="center" rowspan="1" colspan="1">2.29&#x000d7;10<sup>&#x02212;04</sup></td><td align="char" char="." rowspan="1" colspan="1">0.087</td></tr><tr><td align="justify" rowspan="1" colspan="1">MSI1</td><td align="left" rowspan="1" colspan="1">RNA-binding protein, posttranscriptional regulator of proliferative activity</td><td align="char" char="." rowspan="1" colspan="1">26.1</td><td align="char" char="." rowspan="1" colspan="1">-0.351</td><td align="char" char="." rowspan="1" colspan="1">-0.176</td><td align="char" char="." rowspan="1" colspan="1">-0.487</td><td align="char" char="." rowspan="1" colspan="1">0.714</td><td align="center" rowspan="1" colspan="1">2.32&#x000d7;10<sup>&#x02212;04</sup></td><td align="char" char="." rowspan="1" colspan="1">0.087</td></tr><tr><td align="justify" rowspan="1" colspan="1">IKZF1</td><td align="left" rowspan="1" colspan="1">Transcription factor of zinc-finger DNA-binding and lymphocyte differentiation regulator</td><td align="char" char="." rowspan="1" colspan="1">4.5</td><td align="char" char="." rowspan="1" colspan="1">-0.310</td><td align="char" char="." rowspan="1" colspan="1">-0.426</td><td align="char" char="." rowspan="1" colspan="1">0.542</td><td align="char" char="." rowspan="1" colspan="1">1.456</td><td align="center" rowspan="1" colspan="1">2.67&#x000d7;10<sup>&#x02212;04</sup></td><td align="char" char="." rowspan="1" colspan="1">0.089</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><sup>a</sup> Information pertaining to encoded protein function was derived from PubMed Gene unless otherwise noted.</p></fn><fn id="t002fn002"><p><sup>b</sup> Missing% is the proportion of samples with missing values on this protein among all 88 samples.</p></fn><fn id="t002fn003"><p><sup>c</sup> Average expression level was presented in median M values for each protein.</p></fn><fn id="t002fn004"><p><sup>d</sup> Effect size was the mean difference of M values between two treatment periods standardized by standard deviation of average expression in placebo period.</p></fn><fn id="t002fn005"><p><sup>e</sup> Fold-change was the standardized ratio between median M values of aspirin and placebo treatment. A fold change &#x0003e;1 indicated greater antibody expression after aspirin treatment compared to placebo; a fold change &#x0003c;1 indicated lower expression after aspirin treatment.</p></fn><fn id="t002fn006"><p><sup>f</sup> P-values were obtained from mixed linear regression model, adjusted for batch effect, sample position, gender and genotype.</p></fn><fn id="t002fn007"><p><sup>g</sup> P-values were adjusted for false discovery rate using Benjamini-Horchberg procedure.</p></fn></table-wrap-foot></table-wrap><p>Analyses of differences in individual protein expression levels were also undertaken stratified by sex (<xref ref-type="supplementary-material" rid="pone.0178444.s004">S1 Table</xref>). For the nine proteins that were statistically different in the overall analysis, the direction of effect (increased or decreased) was consistent across men and women; however, none of the within-group changes in protein levels was statistically significant after FDR correction, probably due to reduced sample size in subgroup analyses.</p><p>In gene-set analyses using the SAFE framework, a total of 257 KEGG pathways and 1139 GO pathways were tested. Among them, 21 KEGG and 63 GO pathways were statistically significantly different on aspirin than placebo (p-value&#x0003c;0.05); however, none of these gene categories reached statistical significance after FDR correction at significance level of 0.1 (<xref ref-type="supplementary-material" rid="pone.0178444.s005">S2 Table</xref>).</p></sec><sec sec-type="conclusions" id="sec009"><title>Discussion</title><p>In this placebo-controlled randomized crossover trial among healthy individuals, plasma levels of nine of the total of ~3,000 antibodies were significantly different between 60-day regular-dose aspirin and placebo, after adjustment for FDR at 0.1. Among these nine proteins, six had higher expression levels, and three were lower on aspirin than placebo. These proteins play important roles in various pathways, including the mitochondrial Kreb&#x02019;s cycle, DNA base-pair repair, and inflammation. However, when correcting for multiple comparisons, we did not identify overall pathways that were statistically significantly different between aspirin and placebo.</p><p>The protein with the most significant difference between treatments was SDHC; plasma levels were lower after aspirin treatment. SDHC is a subunit of succinate dehydrogenase (SDH), a key enzyme complex of the mitochondrial tricarboxylic acid (TCA) cycle, which oxidizes succinate to fumarate [<xref rid="pone.0178444.ref038" ref-type="bibr">38</xref>]. As one part of SDH (also called complex II), it also facilitates transfer of electrons to coenzyme Q (ubiquinone) [<xref rid="pone.0178444.ref039" ref-type="bibr">39</xref>]. Aspirin has been shown to interfere with mitochondrial function [<xref rid="pone.0178444.ref040" ref-type="bibr">40</xref>], as well as inhibit the activity of SDH in rats [<xref rid="pone.0178444.ref041" ref-type="bibr">41</xref>]. Further, repeated mild inhibition of oxidative phosphorylation via inhibition of SDH protects against the decrease in ATP that usually accompanies severe hypoxia and thus can act as neuroprotection [<xref rid="pone.0178444.ref042" ref-type="bibr">42</xref>]. Treatment with aspirin has also been shown <italic>in vivo</italic> to slow down the decline of intracellular ATP by this mechanism of inhibiting SDH [<xref rid="pone.0178444.ref043" ref-type="bibr">43</xref>] and therefore to protect against hypoxia, a common hallmark of tumors that promotes metabolic adaptations and angiogenesis [<xref rid="pone.0178444.ref044" ref-type="bibr">44</xref>]. Furthermore, accumulation of succinate, due to reduced efficiency of SDHC, results in the stabilization of HIF1-&#x003b1;, the degradation of which is promoted by the oncometabolite (R)-2-hydroxyglutarate [<xref rid="pone.0178444.ref045" ref-type="bibr">45</xref>]. Metabolomic analysis in the present study has shown that plasma concentrations of 2-hydroxyglutarate decreased after aspirin treatment in both men and women (p = 0.005) [<xref rid="pone.0178444.ref026" ref-type="bibr">26</xref>]. It is relevant that plasma concentration of HIF1-&#x003b1; was lower after aspirin treatment among carriers of wild <italic>UGT1A6*1/*1</italic> genotype (Data not shown; p = 6.2&#x000d7;10<sup>&#x02212;05</sup>; adjusted p-value = 0.186), but not among carriers of <italic>UGT1A6*2/*2</italic> genotype, suggesting that the genotypes of <italic>UGT1A6</italic>, which encodes a UDP-glucuronosyltransferase that participates in glucuronidation of aspirin [<xref rid="pone.0178444.ref046" ref-type="bibr">46</xref>], may modulate the effect of aspirin on downstream metabolic functions. In summary, results from our proteomic analyses, as well as those from metabolomic analyses support a possible additional mechanism for aspirin in cancer prevention.</p><p>The expression level of MYH1 was also statistically significantly higher by 62% on aspirin than placebo. As a member of the human homologue of the base excision repair (BER) gene, MYH1 is a DNA glycosylase that removes adenine mispaired with 8-hydroxyguanine from DNA and protects against oxidative DNA damage [<xref rid="pone.0178444.ref047" ref-type="bibr">47</xref>, <xref rid="pone.0178444.ref048" ref-type="bibr">48</xref>]. Inherited variants in <italic>MYH</italic> that cause reduced enzyme function have been associated with significantly increased risk of familial and sporadic CRC in observational studies [<xref rid="pone.0178444.ref049" ref-type="bibr">49</xref>&#x02013;<xref rid="pone.0178444.ref052" ref-type="bibr">52</xref>]. In addition, the prevalence of low-frequency microsatellite instability (MSI) has been found to be higher among <italic>MYH</italic> mutation carriers [<xref rid="pone.0178444.ref051" ref-type="bibr">51</xref>, <xref rid="pone.0178444.ref053" ref-type="bibr">53</xref>], suggesting possible interaction between the BER and MSI pathways. However, most previous observational studies assessed the association between germline mutations of <italic>MYH</italic> and CRC risk, whereas our study directly measured the plasma level of MYH1. Our findings suggest that environmental factors, such as aspirin, may also have an effect on enzyme levels, regardless of genetic background.</p><p>Similarly, NFKBIE was 63% higher on average on aspirin than placebo. NFKBIE is involved in the NF-&#x003ba;B signaling pathway. After cellular stimulation, NFKBIE is highly induced to bind the NF-&#x003ba;B dimer, and provides negative feedback regulation that inhibits NF-&#x003ba;B DNA-binding activity and prevents its nuclear accumulation [<xref rid="pone.0178444.ref054" ref-type="bibr">54</xref>]. As the NF-&#x003ba;B pathway plays an important role in chronic inflammation and tumor promotion, reduction of NF-&#x003ba;B activity is critical in inhibiting the production of pro-inflammatory cytokines [<xref rid="pone.0178444.ref055" ref-type="bibr">55</xref>, <xref rid="pone.0178444.ref056" ref-type="bibr">56</xref>]. In an observational study among 315 chronic lymphocytic leukemia (CLL) patients, targeted deep sequencing of 18 core complex genes within the NF-&#x003ba;B pathway found that the most frequently mutated genes was <italic>NFKBIE</italic>; further screening revealed that truncated NFKBIE predominated in patients with poor prognosis [<xref rid="pone.0178444.ref057" ref-type="bibr">57</xref>]. Similarly, exome sequencing has also suggested that NFKBIE was highly mutated among melanoma patients [<xref rid="pone.0178444.ref058" ref-type="bibr">58</xref>]. Aspirin has been found to inhibit I&#x003ba;B kinase (IKK) &#x003b2;, which inhibits NF-&#x003ba;B inhibitors by phosphorylation [<xref rid="pone.0178444.ref059" ref-type="bibr">59</xref>]. In a nested case-control study, polymorphisms in I&#x003ba;BK&#x003b2; were associated with lower CRC risk and the association was stronger among current NSAID users [<xref rid="pone.0178444.ref011" ref-type="bibr">11</xref>]. Findings from our study are among the first in humans to suggest a biologic interaction between aspirin and NFKBIE, thus providing further support for the likelihood that the NF-&#x003ba;B signaling pathway is involved in one of the mechanisms of action of aspirin.</p><p>Among the other significant proteins, aspirin treatment was associated with 29% lower level of Musashi1 (MSI1), a neural RNA-binding protein. A previous study among colon cancer patients has shown that overexpression of MSI1 in colon cancer lesions, compared to paired normal colonic mucosa, was associated with poorer metastasis-free survival and poorer overall survival [<xref rid="pone.0178444.ref060" ref-type="bibr">60</xref>]. A variety of other potential mechanisms have also been suggested by our findings, including those involving NR2F1 as a nuclear hormone receptor, Forkhead Box O1 (FOXO1) in Akt-mTOR signaling pathway, and KHDRBS3 in RNA-binding and cell-cycle control. Several of these have limited evidence for a relationship with aspirin in humans, probably due to the fact that most previous human studies have focused on candidate genes, proteins, or pathways. Randomized controlled trials of aspirin conducted among patients with cardiovascular disease found statistically significant reductions in circulating concentrations of high-sensitivity C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-&#x003b1;), interleukin-6 (IL-6), and thromboxane B2 (TXB2) [<xref rid="pone.0178444.ref061" ref-type="bibr">61</xref>&#x02013;<xref rid="pone.0178444.ref063" ref-type="bibr">63</xref>].</p><p>Compared to previous human studies of aspirin or other NSAIDs, our study has the strength that our antibody microarray has a high coverage of the proteome (2,100 proteins from 3,000 antibodies), which allowed for more complex proteomic profiling of the impact of aspirin. Most of the proteins that differed significantly between aspirin and placebo treatment are involved in various pathways associated with carcinogenesis, illustrating the potential range of biologic effects of aspirin <italic>in vivo</italic>. Secondly, most of the previous studies were focused on mechanisms inhibited by aspirin in tumor cells or in patients with a focus on tumor progression; ours is among the first to directly evaluate the effects of aspirin among healthy individuals. Therefore, we had the opportunity to identify, agnostically, proteins and mechanisms that are promoted by aspirin treatment; this, nonetheless, remains relevant to understanding how aspirin prevents tumor progression. In addition, the crossover design allowed participants to serve as their own control, which minimized unmeasured inter-individual variability. Because the samples from the same participant were randomly ordered and analyzed within the same batch, additional adjustment for batch effects and sample positions did not change the results. There was also a 3-month wash-out period between treatments (longer than the usual 60-day periods); this minimizes carry-over effects.</p><p>There are also some limitations. First, our analysis was primarily designed to examine the signaling effects of aspirin and has no specific hypothesis or protein to validate. Subsequent steps would involve testing on another set of subjects who took aspirin or placebo but these samples are not available to us at this time. Second, the duration of treatment was two months, and this may not characterize the long-term effects of aspirin use in cancer prevention. Thirdly, our sample size was relatively small and lacked substantial as plasma protein levels were not the main outcome of the intervention. Effect sizes were also small which may reflect the fact that all the participants were generally healthy and therefore would have had relatively low expression of pro-inflammatory proteins; this, in turn would leave less room for change with aspirin intervention. Furthermore, the expression levels of proteins are context-specific: our findings using plasma may differ from those in other tissues, such as colon mucosa. Six of the nine proteins typically are found in the nucleus, so their presence in plasma might result from cellular leakage/damage or exosome formation. In support of the latter, aspirin has been reported to affect the content of platelet-derived exosomes [<xref rid="pone.0178444.ref064" ref-type="bibr">64</xref>]. Lastly, we used a liberal significance level of 0.1 for FDR adjustment. Although a higher threshold was used to identify more possible candidates, it might also lead to more false positive results. Therefore, further investigations of these identified proteins are needed.</p><p>To our knowledge, this is the first randomized trial to systematically evaluate the effect of aspirin on plasma protein profiles in healthy men and women. We identified several proteins that differed significantly between aspirin and placebo, some of which have been previously reported as playing a role in inflammation and carcinogenesis. The involvement of various biologic pathways suggests that the chemopreventive mechanisms of aspirin in humans are complex. Larger, confirmatory studies with a longer period of aspirin exposure are needed.</p></sec><sec sec-type="supplementary-material" id="sec010"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0178444.s001"><label>S1 Data File</label><caption><title>Participant information.</title><p>(XLSX)</p></caption><media xlink:href="pone.0178444.s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0178444.s002"><label>S2 Data File</label><caption><title>Microarray data.</title><p>(XLSX)</p></caption><media xlink:href="pone.0178444.s002.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0178444.s003"><label>S1 Fig</label><caption><title>Flow chart of participant enrollment and study design.</title><p>(DOCX)</p></caption><media xlink:href="pone.0178444.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0178444.s004"><label>S1 Table</label><caption><title>Plasma level differences in the expression of the nine significant proteins, stratified by sex.</title><p>(DOCX)</p></caption><media xlink:href="pone.0178444.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0178444.s005"><label>S2 Table</label><caption><title>List of gene sets with unadjusted p-values &#x0003c;0.05.</title><p>(DOCX)</p></caption><media xlink:href="pone.0178444.s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0178444.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Algra</surname><given-names>AM</given-names></name>, <name><surname>Rothwell</surname><given-names>PM</given-names></name>. <article-title>Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials</article-title>. <source>Lancet Oncol</source>
<year>2012</year>;<volume>13</volume>:<fpage>518</fpage>&#x02013;<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(12)70112-2">10.1016/S1470-2045(12)70112-2</ext-link></comment>
<pub-id pub-id-type="pmid">22440112</pub-id></mixed-citation></ref><ref id="pone.0178444.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Murff</surname><given-names>HJ</given-names></name>, <name><surname>Shrubsole</surname><given-names>MJ</given-names></name>, <name><surname>Chen</surname><given-names>Z</given-names></name>, <name><surname>Smalley</surname><given-names>WE</given-names></name>, <name><surname>Chen</surname><given-names>H</given-names></name>, <name><surname>Shyr</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Nonsteroidal anti-inflammatory drug use and risk of adenomatous and hyperplastic polyps</article-title>. <source>Cancer Prev Res (Phila)</source>
<year>2011</year>;<volume>4</volume>:<fpage>1799</fpage>&#x02013;<lpage>807</lpage>.<pub-id pub-id-type="pmid">21764857</pub-id></mixed-citation></ref><ref id="pone.0178444.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Rothwell</surname><given-names>PM</given-names></name>, <name><surname>Wilson</surname><given-names>M</given-names></name>, <name><surname>Elwin</surname><given-names>CE</given-names></name>, <name><surname>Norrving</surname><given-names>B</given-names></name>, <name><surname>Algra</surname><given-names>A</given-names></name>, <name><surname>Warlow</surname><given-names>CP</given-names></name>, <etal>et al</etal>
<article-title>Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials</article-title>. <source>Lancet</source>
<year>2010</year>;<volume>376</volume>:<fpage>1741</fpage>&#x02013;<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(10)61543-7">10.1016/S0140-6736(10)61543-7</ext-link></comment>
<pub-id pub-id-type="pmid">20970847</pub-id></mixed-citation></ref><ref id="pone.0178444.ref004"><label>4</label><mixed-citation publication-type="book"><name><surname>Chubak</surname><given-names>J</given-names></name>, <name><surname>Kamineni</surname><given-names>A</given-names></name>, <name><surname>Buist</surname><given-names>DSM</given-names></name>, <name><surname>Anderson</surname><given-names>ML</given-names></name>, <name><surname>Whitlock</surname><given-names>EP</given-names></name>. <edition>Edtion ed</edition>
<source>Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the US Preventive Services Task Force</source>. <publisher-loc>Rockville (MD)</publisher-loc>, <year>2015</year>.</mixed-citation></ref><ref id="pone.0178444.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Thun</surname><given-names>MJ</given-names></name>, <name><surname>Henley</surname><given-names>SJ</given-names></name>, <name><surname>Patrono</surname><given-names>C</given-names></name>. <article-title>Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues</article-title>. <source>J Natl Cancer Inst</source>
<year>2002</year>;<volume>94</volume>:<fpage>252</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="pmid">11854387</pub-id></mixed-citation></ref><ref id="pone.0178444.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Gupta</surname><given-names>RA</given-names></name>, <name><surname>Dubois</surname><given-names>RN</given-names></name>. <article-title>Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2</article-title>. <source>Nat Rev Cancer</source>
<year>2001</year>;<volume>1</volume>:<fpage>11</fpage>&#x02013;<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/35094017">10.1038/35094017</ext-link></comment>
<pub-id pub-id-type="pmid">11900248</pub-id></mixed-citation></ref><ref id="pone.0178444.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Ulrich</surname><given-names>CM</given-names></name>, <name><surname>Bigler</surname><given-names>J</given-names></name>, <name><surname>Potter</surname><given-names>JD</given-names></name>. <article-title>Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics</article-title>. <source>Nat Rev Cancer</source>
<year>2006</year>;<volume>6</volume>:<fpage>130</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrc1801">10.1038/nrc1801</ext-link></comment>
<pub-id pub-id-type="pmid">16491072</pub-id></mixed-citation></ref><ref id="pone.0178444.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Bos</surname><given-names>CL</given-names></name>, <name><surname>Kodach</surname><given-names>LL</given-names></name>, <name><surname>van den Brink</surname><given-names>GR</given-names></name>, <name><surname>Diks</surname><given-names>SH</given-names></name>, <name><surname>van Santen</surname><given-names>MM</given-names></name>, <name><surname>Richel</surname><given-names>DJ</given-names></name>, <etal>et al</etal>
<article-title>Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A</article-title>. <source>Oncogene</source>
<year>2006</year>;<volume>25</volume>:<fpage>6447</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.onc.1209658">10.1038/sj.onc.1209658</ext-link></comment>
<pub-id pub-id-type="pmid">16878161</pub-id></mixed-citation></ref><ref id="pone.0178444.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Pan</surname><given-names>MR</given-names></name>, <name><surname>Chang</surname><given-names>HC</given-names></name>, <name><surname>Hung</surname><given-names>WC</given-names></name>. <article-title>Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases</article-title>. <source>Cell Signal</source>
<year>2008</year>;<volume>20</volume>:<fpage>1134</fpage>&#x02013;<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cellsig.2008.02.004">10.1016/j.cellsig.2008.02.004</ext-link></comment>
<pub-id pub-id-type="pmid">18374541</pub-id></mixed-citation></ref><ref id="pone.0178444.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Nan</surname><given-names>H</given-names></name>, <name><surname>Morikawa</surname><given-names>T</given-names></name>, <name><surname>Suuriniemi</surname><given-names>M</given-names></name>, <name><surname>Imamura</surname><given-names>Y</given-names></name>, <name><surname>Werner</surname><given-names>L</given-names></name>, <name><surname>Kuchiba</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations</article-title>. <source>J Natl Cancer Inst</source>
<year>2013</year>;<volume>105</volume>:<fpage>1852</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jnci/djt331">10.1093/jnci/djt331</ext-link></comment>
<pub-id pub-id-type="pmid">24317174</pub-id></mixed-citation></ref><ref id="pone.0178444.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Seufert</surname><given-names>BL</given-names></name>, <name><surname>Poole</surname><given-names>EM</given-names></name>, <name><surname>Whitton</surname><given-names>J</given-names></name>, <name><surname>Xiao</surname><given-names>L</given-names></name>, <name><surname>Makar</surname><given-names>KW</given-names></name>, <name><surname>Campbell</surname><given-names>PT</given-names></name>, <etal>et al</etal>
<article-title>IkappaBKbeta and NFkappaB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry</article-title>. <source>Carcinogenesis</source>
<year>2013</year>;<volume>34</volume>:<fpage>79</fpage>&#x02013;<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/carcin/bgs296">10.1093/carcin/bgs296</ext-link></comment>
<pub-id pub-id-type="pmid">23002237</pub-id></mixed-citation></ref><ref id="pone.0178444.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Andersen</surname><given-names>V</given-names></name>, <name><surname>Christensen</surname><given-names>J</given-names></name>, <name><surname>Overvad</surname><given-names>K</given-names></name>, <name><surname>Tjonneland</surname><given-names>A</given-names></name>, <name><surname>Vogel</surname><given-names>U</given-names></name>. <article-title>Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes</article-title>. <source>BMC Cancer</source>
<year>2010</year>;<volume>10</volume>:<fpage>484</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2407-10-484">10.1186/1471-2407-10-484</ext-link></comment>
<pub-id pub-id-type="pmid">20836841</pub-id></mixed-citation></ref><ref id="pone.0178444.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Nan</surname><given-names>H</given-names></name>, <name><surname>Hutter</surname><given-names>CM</given-names></name>, <name><surname>Lin</surname><given-names>Y</given-names></name>, <name><surname>Jacobs</surname><given-names>EJ</given-names></name>, <name><surname>Ulrich</surname><given-names>CM</given-names></name>, <name><surname>White</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants</article-title>. <source>JAMA</source>
<year>2015</year>;<volume>313</volume>:<fpage>1133</fpage>&#x02013;<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.2015.1815">10.1001/jama.2015.1815</ext-link></comment>
<pub-id pub-id-type="pmid">25781442</pub-id></mixed-citation></ref><ref id="pone.0178444.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Andersen</surname><given-names>V</given-names></name>, <name><surname>Vogel</surname><given-names>U</given-names></name>. <article-title>Systematic review: interactions between aspirin, and other nonsteroidal anti-inflammatory drugs, and polymorphisms in relation to colorectal cancer</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2014</year>;<volume>40</volume>:<fpage>147</fpage>&#x02013;<lpage>59</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/apt.12807">10.1111/apt.12807</ext-link></comment>
<pub-id pub-id-type="pmid">24889212</pub-id></mixed-citation></ref><ref id="pone.0178444.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>van Erk</surname><given-names>MJ</given-names></name>, <name><surname>Wopereis</surname><given-names>S</given-names></name>, <name><surname>Rubingh</surname><given-names>C</given-names></name>, <name><surname>van Vliet</surname><given-names>T</given-names></name>, <name><surname>Verheij</surname><given-names>E</given-names></name>, <name><surname>Cnubben</surname><given-names>NH</given-names></name>, <etal>et al</etal>
<article-title>Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study</article-title>. <source>BMC Med Genomics</source>
<year>2010</year>;<volume>3</volume>:<fpage>5</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1755-8794-3-5">10.1186/1755-8794-3-5</ext-link></comment>
<pub-id pub-id-type="pmid">20178593</pub-id></mixed-citation></ref><ref id="pone.0178444.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Navarro</surname><given-names>S</given-names></name>
<name><surname>W</surname><given-names>E</given-names></name>, <name><surname>Kantor</surname><given-names>ED</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Rho</surname><given-names>J</given-names></name>, <name><surname>Song</surname><given-names>X</given-names></name>, <name><surname>Milne</surname><given-names>GL</given-names></name>, <name><surname>Lampe</surname><given-names>PD</given-names></name>, <name><surname>Lampe</surname><given-names>JW</given-names></name>. <article-title>Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans</article-title>. <source>PLoS One</source>
<year>2015</year>;<volume>10</volume>:<fpage>e0117534</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0117534">10.1371/journal.pone.0117534</ext-link></comment>
<pub-id pub-id-type="pmid">25719429</pub-id></mixed-citation></ref><ref id="pone.0178444.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Ramirez</surname><given-names>AB</given-names></name>, <name><surname>Loch</surname><given-names>CM</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Wayner</surname><given-names>EA</given-names></name>, <etal>et al</etal>
<article-title>Use of a single-chain antibody library for ovarian cancer biomarker discovery</article-title>. <source>Mol Cell Proteomics</source>
<year>2010</year>;<volume>9</volume>:<fpage>1449</fpage>&#x02013;<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/mcp.M900496-MCP200">10.1074/mcp.M900496-MCP200</ext-link></comment>
<pub-id pub-id-type="pmid">20467042</pub-id></mixed-citation></ref><ref id="pone.0178444.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Loch</surname><given-names>CM</given-names></name>, <name><surname>Ramirez</surname><given-names>AB</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Sather</surname><given-names>CL</given-names></name>, <name><surname>Delrow</surname><given-names>JJ</given-names></name>, <name><surname>Scholler</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Use of high density antibody arrays to validate and discover cancer serum biomarkers</article-title>. <source>Mol Oncol</source>
<year>2007</year>;<volume>1</volume>:<fpage>313</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molonc.2007.08.004">10.1016/j.molonc.2007.08.004</ext-link></comment>
<pub-id pub-id-type="pmid">19383305</pub-id></mixed-citation></ref><ref id="pone.0178444.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Buas</surname><given-names>MF</given-names></name>, <name><surname>Rho</surname><given-names>JH</given-names></name>, <name><surname>Chai</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Lampe</surname><given-names>PD</given-names></name>, <name><surname>Li</surname><given-names>CI</given-names></name>. <article-title>Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study</article-title>. <source>Breast Cancer Res Treat</source>
<year>2015</year>;<volume>153</volume>:<fpage>445</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-015-3554-5">10.1007/s10549-015-3554-5</ext-link></comment>
<pub-id pub-id-type="pmid">26319120</pub-id></mixed-citation></ref><ref id="pone.0178444.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Mirus</surname><given-names>JE</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>CI</given-names></name>, <name><surname>Lokshin</surname><given-names>AE</given-names></name>, <name><surname>Prentice</surname><given-names>RL</given-names></name>, <name><surname>Hingorani</surname><given-names>SR</given-names></name>, <etal>et al</etal>
<article-title>Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer</article-title>. <source>Clin Cancer Res</source>
<year>2015</year>;<volume>21</volume>:<fpage>1764</fpage>&#x02013;<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-13-3474">10.1158/1078-0432.CCR-13-3474</ext-link></comment>
<pub-id pub-id-type="pmid">25589628</pub-id></mixed-citation></ref><ref id="pone.0178444.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Mirus</surname><given-names>JE</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Hollingsworth</surname><given-names>MA</given-names></name>, <name><surname>Solan</surname><given-names>JL</given-names></name>, <name><surname>Lampe</surname><given-names>PD</given-names></name>, <name><surname>Hingorani</surname><given-names>SR</given-names></name>. <article-title>Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease</article-title>. <source>Mol Cell Proteomics</source>
<year>2014</year>;<volume>13</volume>:<fpage>3484</fpage>&#x02013;<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/mcp.M113.036517">10.1074/mcp.M113.036517</ext-link></comment>
<pub-id pub-id-type="pmid">25225358</pub-id></mixed-citation></ref><ref id="pone.0178444.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Rho</surname><given-names>JH</given-names></name>, <name><surname>Ladd</surname><given-names>JJ</given-names></name>, <name><surname>Li</surname><given-names>CI</given-names></name>, <name><surname>Potter</surname><given-names>JD</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Shelley</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Protein and glycomic plasma markers for early detection of adenoma and colon cancer</article-title>. <source>Gut</source>
<year>2016</year>: <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/gutjnl-2016-312794">10.1136/gutjnl-2016-312794</ext-link></comment>
<pub-id pub-id-type="pmid">27821646</pub-id></mixed-citation></ref><ref id="pone.0178444.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Garrison</surname><given-names>CB</given-names></name>, <name><surname>Lastwika</surname><given-names>KJ</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>CI</given-names></name>, <name><surname>Lampe</surname><given-names>PD</given-names></name>. <article-title>Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity</article-title>. <source>J Proteome Res</source>
<year>2017</year>;<volume>16</volume>:<fpage>274</fpage>&#x02013;<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/acs.jproteome.6b00611">10.1021/acs.jproteome.6b00611</ext-link></comment>
<pub-id pub-id-type="pmid">27769113</pub-id></mixed-citation></ref><ref id="pone.0178444.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Bohm</surname><given-names>J</given-names></name>, <name><surname>Pianka</surname><given-names>F</given-names></name>, <name><surname>Stuttgen</surname><given-names>N</given-names></name>, <name><surname>Rho</surname><given-names>J</given-names></name>, <name><surname>Gigic</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Discovery of novel plasma proteins as biomarkers for the development of incisional hernias after midline incision in patients with colorectal cancer: The ColoCare study</article-title>. <source>Surgery</source>
<year>2017</year>;<volume>161</volume>:<fpage>808</fpage>&#x02013;<lpage>17</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.surg.2016.08.025">10.1016/j.surg.2016.08.025</ext-link></comment>
<pub-id pub-id-type="pmid">27745870</pub-id></mixed-citation></ref><ref id="pone.0178444.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Thomas</surname><given-names>SS</given-names></name>, <name><surname>Makar</surname><given-names>KW</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Zheng</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>P</given-names></name>, <name><surname>Levy</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial</article-title>. <source>BMC Med Genet</source>
<year>2015</year>;<volume>16</volume>:<fpage>18</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12881-015-0161-6">10.1186/s12881-015-0161-6</ext-link></comment>
<pub-id pub-id-type="pmid">25927723</pub-id></mixed-citation></ref><ref id="pone.0178444.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Liesenfeld</surname><given-names>DB</given-names></name>, <name><surname>Botma</surname><given-names>A</given-names></name>, <name><surname>Habermann</surname><given-names>N</given-names></name>, <name><surname>Toth</surname><given-names>R</given-names></name>, <name><surname>Weigel</surname><given-names>C</given-names></name>, <name><surname>Popanda</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>
<year>2016</year>;<volume>25</volume>:<fpage>180</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1055-9965.EPI-15-0697">10.1158/1055-9965.EPI-15-0697</ext-link></comment>
<pub-id pub-id-type="pmid">26585118</pub-id></mixed-citation></ref><ref id="pone.0178444.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Navarro</surname><given-names>SL</given-names></name>, <name><surname>Saracino</surname><given-names>MR</given-names></name>, <name><surname>Makar</surname><given-names>KW</given-names></name>, <name><surname>Thomas</surname><given-names>SS</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Zheng</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Determinants of aspirin metabolism in healthy men and women: effects of dietary inducers of UDP-glucuronosyltransferases</article-title>. <source>J Nutrigenet Nutrigenomics</source>
<year>2011</year>;<volume>4</volume>:<fpage>110</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000327782">10.1159/000327782</ext-link></comment>
<pub-id pub-id-type="pmid">21625173</pub-id></mixed-citation></ref><ref id="pone.0178444.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Rho</surname><given-names>JH</given-names></name>, <name><surname>Lampe</surname><given-names>PD</given-names></name>. <article-title>High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays</article-title>. <source>J Proteome Res</source>
<year>2013</year>;<volume>12</volume>:<fpage>2311</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/pr4001674">10.1021/pr4001674</ext-link></comment>
<pub-id pub-id-type="pmid">23541305</pub-id></mixed-citation></ref><ref id="pone.0178444.ref029"><label>29</label><mixed-citation publication-type="book"><name><surname>Smyth</surname><given-names>GK</given-names></name>. <chapter-title>Limma: linear models for microarray data</chapter-title>
<edition>Edtion ed</edition> In: <name><surname>Gentleman</surname><given-names>R</given-names></name>, <name><surname>Carey</surname><given-names>V</given-names></name>, <name><surname>Dudoit</surname><given-names>S</given-names></name>, <name><surname>Irizarry</surname><given-names>R</given-names></name>, <name><surname>Huber</surname><given-names>I.W</given-names></name>, ed. <source>Bioinformatics and Computational Biology Solutions Using R and Bioconductor</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2005</year>:<fpage>397</fpage>&#x02013;<lpage>420</lpage>.</mixed-citation></ref><ref id="pone.0178444.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>CI</given-names></name>, <name><surname>Mirus</surname><given-names>JE</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Ramirez</surname><given-names>AB</given-names></name>, <name><surname>Ladd</surname><given-names>JJ</given-names></name>, <name><surname>Prentice</surname><given-names>RL</given-names></name>, <etal>et al</etal>
<article-title>Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study</article-title>. <source>Breast Cancer Res Treat</source>
<year>2012</year>;<volume>135</volume>:<fpage>611</fpage>&#x02013;<lpage>8</lpage>. PNC3439142. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-012-2204-4">10.1007/s10549-012-2204-4</ext-link></comment>
<pub-id pub-id-type="pmid">22903690</pub-id></mixed-citation></ref><ref id="pone.0178444.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Ramirez</surname><given-names>AB</given-names></name>, <name><surname>Lampe</surname><given-names>PD</given-names></name>. <article-title>Discovery and validation of ovarian cancer biomarkers utilizing high density antibody microarrays</article-title>. <source>Cancer Biomark</source>
<year>2010</year>;<volume>8</volume>:<fpage>293</fpage>&#x02013;<lpage>307</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3233/CBM-2011-0215">10.3233/CBM-2011-0215</ext-link></comment>
<pub-id pub-id-type="pmid">22045360</pub-id></mixed-citation></ref><ref id="pone.0178444.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Bartko</surname><given-names>JJ</given-names></name>. <article-title>The intraclass correlation coefficient as a measure of reliability</article-title>. <source>Psychol Rep</source>
<year>1966</year>;<volume>19</volume>:<fpage>3</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2466/pr0.1966.19.1.3">10.2466/pr0.1966.19.1.3</ext-link></comment>
<pub-id pub-id-type="pmid">5942109</pub-id></mixed-citation></ref><ref id="pone.0178444.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>H</given-names></name>, <name><surname>Golub</surname><given-names>GH</given-names></name>, <name><surname>Park</surname><given-names>H</given-names></name>. <article-title>Missing value estimation for DNA microarray gene expression data: local least squares imputation</article-title>. <source>Bioinformatics</source>
<year>2005</year>;<volume>21</volume>:<fpage>187</fpage>&#x02013;<lpage>98</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/bth499">10.1093/bioinformatics/bth499</ext-link></comment>
<pub-id pub-id-type="pmid">15333461</pub-id></mixed-citation></ref><ref id="pone.0178444.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Smyth</surname><given-names>GK</given-names></name>. <article-title>Linear models and empirical bayes methods for assessing differential expression in microarray experiments</article-title>. <source>Stat Appl Genet Mol Biol</source>
<year>2004</year>;<volume>3</volume>:Article3.</mixed-citation></ref><ref id="pone.0178444.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Barry</surname><given-names>WT</given-names></name>, <name><surname>Nobel</surname><given-names>AB</given-names></name>, <name><surname>Wright</surname><given-names>FA</given-names></name>. <article-title>Significance analysis of functional categories in gene expression studies: a structured permutation approach</article-title>. <source>Bioinformatics</source>
<year>2005</year>;<volume>21</volume>:<fpage>1943</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/bti260">10.1093/bioinformatics/bti260</ext-link></comment>
<pub-id pub-id-type="pmid">15647293</pub-id></mixed-citation></ref><ref id="pone.0178444.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>D</given-names></name>, <name><surname>Smyth</surname><given-names>GK</given-names></name>. <article-title>Camera: a competitive gene set test accounting for inter-gene correlation</article-title>. <source>Nucleic Acids Res</source>
<year>2012</year>;<volume>40</volume>:<fpage>e133</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gks461">10.1093/nar/gks461</ext-link></comment>
<pub-id pub-id-type="pmid">22638577</pub-id></mixed-citation></ref><ref id="pone.0178444.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>LS</given-names></name>, <name><surname>Paul</surname><given-names>D</given-names></name>, <name><surname>Prentice</surname><given-names>RL</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name>. <article-title>A regularized Hotelling's test for pathway analysis in proteomic studies</article-title>. <source>J Am Stat Assoc</source>
<year>2011</year>;<volume>106</volume>:<fpage>1345</fpage>&#x02013;<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1198/jasa.2011.ap10599">10.1198/jasa.2011.ap10599</ext-link></comment>
<pub-id pub-id-type="pmid">23997374</pub-id></mixed-citation></ref><ref id="pone.0178444.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Desideri</surname><given-names>E</given-names></name>, <name><surname>Vegliante</surname><given-names>R</given-names></name>, <name><surname>Ciriolo</surname><given-names>MR</given-names></name>. <article-title>Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity</article-title>. <source>Cancer Lett</source>
<year>2015</year>;<volume>356</volume>:<fpage>217</fpage>&#x02013;<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.canlet.2014.02.023">10.1016/j.canlet.2014.02.023</ext-link></comment>
<pub-id pub-id-type="pmid">24614286</pub-id></mixed-citation></ref><ref id="pone.0178444.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Yankovskaya</surname><given-names>V</given-names></name>, <name><surname>Horsefield</surname><given-names>R</given-names></name>, <name><surname>Tornroth</surname><given-names>S</given-names></name>, <name><surname>Luna-Chavez</surname><given-names>C</given-names></name>, <name><surname>Miyoshi</surname><given-names>H</given-names></name>, <name><surname>Leger</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Architecture of succinate dehydrogenase and reactive oxygen species generation</article-title>. <source>Science</source>
<year>2003</year>;<volume>299</volume>:<fpage>700</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1079605">10.1126/science.1079605</ext-link></comment>
<pub-id pub-id-type="pmid">12560550</pub-id></mixed-citation></ref><ref id="pone.0178444.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Lutwak-Mann</surname><given-names>C</given-names></name>. <article-title>The effect of salicylate and cinchophen on enzymes and metabolic processes</article-title>. <source>Biochem J</source>
<year>1942</year>;<volume>36</volume>:<fpage>706</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="pmid">16747500</pub-id></mixed-citation></ref><ref id="pone.0178444.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Kaplan</surname><given-names>EH</given-names></name>, <name><surname>Kennedy</surname><given-names>J</given-names></name>, <name><surname>Davis</surname><given-names>J</given-names></name>. <article-title>Effects of salicylate and other benzoates on oxidative enzymes of the tricarboxylic acid cycle in rat tissue homogenates</article-title>. <source>Arch Biochem Biophys</source>
<year>1954</year>;<volume>51</volume>:<fpage>47</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="pmid">13181459</pub-id></mixed-citation></ref><ref id="pone.0178444.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Riepe</surname><given-names>MW</given-names></name>, <name><surname>Niemi</surname><given-names>WN</given-names></name>, <name><surname>Megow</surname><given-names>D</given-names></name>, <name><surname>Ludolph</surname><given-names>AC</given-names></name>, <name><surname>Carpenter</surname><given-names>DO</given-names></name>. <article-title>Mitochondrial oxidation in rat hippocampus can be preconditioned by selective chemical inhibition of succinic dehydrogenase</article-title>. <source>Exp Neurol</source>
<year>1996</year>;<volume>138</volume>:<fpage>15</fpage>&#x02013;<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1006/exnr.1996.0042">10.1006/exnr.1996.0042</ext-link></comment>
<pub-id pub-id-type="pmid">8593890</pub-id></mixed-citation></ref><ref id="pone.0178444.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Riepe</surname><given-names>MW</given-names></name>, <name><surname>Kasischke</surname><given-names>K</given-names></name>, <name><surname>Raupach</surname><given-names>A</given-names></name>. <article-title>Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia</article-title>. <source>Stroke</source>
<year>1997</year>;<volume>28</volume>:<fpage>2006</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="pmid">9341711</pub-id></mixed-citation></ref><ref id="pone.0178444.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Majmundar</surname><given-names>AJ</given-names></name>, <name><surname>Wong</surname><given-names>WJ</given-names></name>, <name><surname>Simon</surname><given-names>MC</given-names></name>. <article-title>Hypoxia-inducible factors and the response to hypoxic stress</article-title>. <source>Mol Cell</source>
<year>2010</year>;<volume>40</volume>:<fpage>294</fpage>&#x02013;<lpage>309</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molcel.2010.09.022">10.1016/j.molcel.2010.09.022</ext-link></comment>
<pub-id pub-id-type="pmid">20965423</pub-id></mixed-citation></ref><ref id="pone.0178444.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Koivunen</surname><given-names>P</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Duncan</surname><given-names>CG</given-names></name>, <name><surname>Lopez</surname><given-names>G</given-names></name>, <name><surname>Lu</surname><given-names>G</given-names></name>, <name><surname>Ramkissoon</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation</article-title>. <source>Nature</source>
<year>2012</year>;<volume>483</volume>:<fpage>484</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature10898">10.1038/nature10898</ext-link></comment>
<pub-id pub-id-type="pmid">22343896</pub-id></mixed-citation></ref><ref id="pone.0178444.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Kuehl</surname><given-names>GE</given-names></name>, <name><surname>Bigler</surname><given-names>J</given-names></name>, <name><surname>Potter</surname><given-names>JD</given-names></name>, <name><surname>Lampe</surname><given-names>JW</given-names></name>. <article-title>Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes</article-title>. <source>Drug Metab Dispos</source>
<year>2006</year>;<volume>34</volume>:<fpage>199</fpage>&#x02013;<lpage>202</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1124/dmd.105.005652">10.1124/dmd.105.005652</ext-link></comment>
<pub-id pub-id-type="pmid">16258079</pub-id></mixed-citation></ref><ref id="pone.0178444.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Slupska</surname><given-names>MM</given-names></name>, <name><surname>Baikalov</surname><given-names>C</given-names></name>, <name><surname>Luther</surname><given-names>WM</given-names></name>, <name><surname>Chiang</surname><given-names>JH</given-names></name>, <name><surname>Wei</surname><given-names>YF</given-names></name>, <name><surname>Miller</surname><given-names>JH</given-names></name>. <article-title>Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY gene whose function is required for the repair of oxidative DNA damage</article-title>. <source>J Bacteriol</source>
<year>1996</year>;<volume>178</volume>:<fpage>3885</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="pmid">8682794</pub-id></mixed-citation></ref><ref id="pone.0178444.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Hayashi</surname><given-names>H</given-names></name>, <name><surname>Tominaga</surname><given-names>Y</given-names></name>, <name><surname>Hirano</surname><given-names>S</given-names></name>, <name><surname>McKenna</surname><given-names>AE</given-names></name>, <name><surname>Nakabeppu</surname><given-names>Y</given-names></name>, <name><surname>Matsumoto</surname><given-names>Y</given-names></name>. <article-title>Replication-associated repair of adenine:8-oxoguanine mispairs by MYH</article-title>. <source>Curr Biol</source>
<year>2002</year>;<volume>12</volume>:<fpage>335</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="pmid">11864576</pub-id></mixed-citation></ref><ref id="pone.0178444.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Al-Tassan</surname><given-names>N</given-names></name>, <name><surname>Chmiel</surname><given-names>NH</given-names></name>, <name><surname>Maynard</surname><given-names>J</given-names></name>, <name><surname>Fleming</surname><given-names>N</given-names></name>, <name><surname>Livingston</surname><given-names>AL</given-names></name>, <name><surname>Williams</surname><given-names>GT</given-names></name>, <etal>et al</etal>
<article-title>Inherited variants of MYH associated with somatic G:C&#x02014;&#x0003e;T:A mutations in colorectal tumors</article-title>. <source>Nat Genet</source>
<year>2002</year>;<volume>30</volume>:<fpage>227</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng828">10.1038/ng828</ext-link></comment>
<pub-id pub-id-type="pmid">11818965</pub-id></mixed-citation></ref><ref id="pone.0178444.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Kambara</surname><given-names>T</given-names></name>, <name><surname>Whitehall</surname><given-names>VL</given-names></name>, <name><surname>Spring</surname><given-names>KJ</given-names></name>, <name><surname>Barker</surname><given-names>MA</given-names></name>, <name><surname>Arnold</surname><given-names>S</given-names></name>, <name><surname>Wynter</surname><given-names>CV</given-names></name>, <etal>et al</etal>
<article-title>Role of inherited defects of MYH in the development of sporadic colorectal cancer</article-title>. <source>Genes Chromosomes Cancer</source>
<year>2004</year>;<volume>40</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/gcc.20011">10.1002/gcc.20011</ext-link></comment>
<pub-id pub-id-type="pmid">15034862</pub-id></mixed-citation></ref><ref id="pone.0178444.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Cleary</surname><given-names>SP</given-names></name>, <name><surname>Cotterchio</surname><given-names>M</given-names></name>, <name><surname>Jenkins</surname><given-names>MA</given-names></name>, <name><surname>Kim</surname><given-names>H</given-names></name>, <name><surname>Bristow</surname><given-names>R</given-names></name>, <name><surname>Green</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study</article-title>. <source>Gastroenterology</source>
<year>2009</year>;<volume>136</volume>:<fpage>1251</fpage>&#x02013;<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/j.gastro.2008.12.050">10.1053/j.gastro.2008.12.050</ext-link></comment>
<pub-id pub-id-type="pmid">19245865</pub-id></mixed-citation></ref><ref id="pone.0178444.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Win</surname><given-names>AK</given-names></name>, <name><surname>Dowty</surname><given-names>JG</given-names></name>, <name><surname>Cleary</surname><given-names>SP</given-names></name>, <name><surname>Kim</surname><given-names>H</given-names></name>, <name><surname>Buchanan</surname><given-names>DD</given-names></name>, <name><surname>Young</surname><given-names>JP</given-names></name>, <etal>et al</etal>
<article-title>Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer</article-title>. <source>Gastroenterology</source>
<year>2014</year>;<volume>146</volume>:<fpage>1208</fpage>&#x02013;<lpage>11</lpage>
<fpage>e1</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/j.gastro.2014.01.022">10.1053/j.gastro.2014.01.022</ext-link></comment>
<pub-id pub-id-type="pmid">24444654</pub-id></mixed-citation></ref><ref id="pone.0178444.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Colebatch</surname><given-names>A</given-names></name>, <name><surname>Hitchins</surname><given-names>M</given-names></name>, <name><surname>Williams</surname><given-names>R</given-names></name>, <name><surname>Meagher</surname><given-names>A</given-names></name>, <name><surname>Hawkins</surname><given-names>NJ</given-names></name>, <name><surname>Ward</surname><given-names>RL</given-names></name>. <article-title>The role of MYH and microsatellite instability in the development of sporadic colorectal cancer</article-title>. <source>Br J Cancer</source>
<year>2006</year>;<volume>95</volume>:<fpage>1239</fpage>&#x02013;<lpage>43</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.bjc.6603421">10.1038/sj.bjc.6603421</ext-link></comment>
<pub-id pub-id-type="pmid">17031395</pub-id></mixed-citation></ref><ref id="pone.0178444.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Kearns</surname><given-names>JD</given-names></name>, <name><surname>Basak</surname><given-names>S</given-names></name>, <name><surname>Werner</surname><given-names>SL</given-names></name>, <name><surname>Huang</surname><given-names>CS</given-names></name>, <name><surname>Hoffmann</surname><given-names>A</given-names></name>. <article-title>IkappaBepsilon provides negative feedback to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression</article-title>. <source>J Cell Biol</source>
<year>2006</year>;<volume>173</volume>:<fpage>659</fpage>&#x02013;<lpage>64</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.200510155">10.1083/jcb.200510155</ext-link></comment>
<pub-id pub-id-type="pmid">16735576</pub-id></mixed-citation></ref><ref id="pone.0178444.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Greten</surname><given-names>FR</given-names></name>, <name><surname>Karin</surname><given-names>M</given-names></name>. <article-title>The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer</article-title>. <source>Cancer Lett</source>
<year>2004</year>;<volume>206</volume>:<fpage>193</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.canlet.2003.08.029">10.1016/j.canlet.2003.08.029</ext-link></comment>
<pub-id pub-id-type="pmid">15013524</pub-id></mixed-citation></ref><ref id="pone.0178444.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Withoff</surname><given-names>S</given-names></name>, <name><surname>Verma</surname><given-names>IM</given-names></name>. <article-title>Inflammation-associated cancer: NF-kappaB is the lynchpin</article-title>. <source>Trends Immunol</source>
<year>2005</year>;<volume>26</volume>:<fpage>318</fpage>&#x02013;<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.it.2005.04.003">10.1016/j.it.2005.04.003</ext-link></comment>
<pub-id pub-id-type="pmid">15922948</pub-id></mixed-citation></ref><ref id="pone.0178444.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Mansouri</surname><given-names>L</given-names></name>, <name><surname>Sutton</surname><given-names>LA</given-names></name>, <name><surname>Ljungstrom</surname><given-names>V</given-names></name>, <name><surname>Bondza</surname><given-names>S</given-names></name>, <name><surname>Arngarden</surname><given-names>L</given-names></name>, <name><surname>Bhoi</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia</article-title>. <source>J Exp Med</source>
<year>2015</year>;<volume>212</volume>:<fpage>833</fpage>&#x02013;<lpage>43</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1084/jem.20142009">10.1084/jem.20142009</ext-link></comment>
<pub-id pub-id-type="pmid">25987724</pub-id></mixed-citation></ref><ref id="pone.0178444.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Shain</surname><given-names>AH</given-names></name>, <name><surname>Garrido</surname><given-names>M</given-names></name>, <name><surname>Botton</surname><given-names>T</given-names></name>, <name><surname>Talevich</surname><given-names>E</given-names></name>, <name><surname>Yeh</surname><given-names>I</given-names></name>, <name><surname>Sanborn</surname><given-names>JZ</given-names></name>, <etal>et al</etal>
<article-title>Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway</article-title>. <source>Nat Genet</source>
<year>2015</year>;<volume>47</volume>:<fpage>1194</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.3382">10.1038/ng.3382</ext-link></comment>
<pub-id pub-id-type="pmid">26343386</pub-id></mixed-citation></ref><ref id="pone.0178444.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Yin</surname><given-names>MJ</given-names></name>, <name><surname>Yamamoto</surname><given-names>Y</given-names></name>, <name><surname>Gaynor</surname><given-names>RB</given-names></name>. <article-title>The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta</article-title>. <source>Nature</source>
<year>1998</year>;<volume>396</volume>:<fpage>77</fpage>&#x02013;<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/23948">10.1038/23948</ext-link></comment>
<pub-id pub-id-type="pmid">9817203</pub-id></mixed-citation></ref><ref id="pone.0178444.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>D</given-names></name>, <name><surname>Peng</surname><given-names>X</given-names></name>, <name><surname>Yan</surname><given-names>D</given-names></name>, <name><surname>Tang</surname><given-names>H</given-names></name>, <name><surname>Huang</surname><given-names>F</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Msi-1 is a predictor of survival and a novel therapeutic target in colon cancer</article-title>. <source>Ann Surg Oncol</source>
<year>2011</year>;<volume>18</volume>:<fpage>2074</fpage>&#x02013;<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1245/s10434-011-1567-9">10.1245/s10434-011-1567-9</ext-link></comment>
<pub-id pub-id-type="pmid">21442350</pub-id></mixed-citation></ref><ref id="pone.0178444.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>XR</given-names></name>, <name><surname>Adhikari</surname><given-names>CM</given-names></name>, <name><surname>Peng</surname><given-names>LY</given-names></name>, <name><surname>Guo</surname><given-names>XG</given-names></name>, <name><surname>Zhai</surname><given-names>YS</given-names></name>, <name><surname>He</surname><given-names>XY</given-names></name>, <etal>et al</etal>
<article-title>Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome</article-title>. <source>J Pharm Pharmacol</source>
<year>2009</year>;<volume>61</volume>:<fpage>1505</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1211/jpp/61.11.0010">10.1211/jpp/61.11.0010</ext-link></comment>
<pub-id pub-id-type="pmid">19903376</pub-id></mixed-citation></ref><ref id="pone.0178444.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Solheim</surname><given-names>S</given-names></name>, <name><surname>Arnesen</surname><given-names>H</given-names></name>, <name><surname>Eikvar</surname><given-names>L</given-names></name>, <name><surname>Hurlen</surname><given-names>M</given-names></name>, <name><surname>Seljeflot</surname><given-names>I</given-names></name>. <article-title>Influence of aspirin on inflammatory markers in patients after acute myocardial infarction</article-title>. <source>Am J Cardiol</source>
<year>2003</year>;<volume>92</volume>:<fpage>843</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="pmid">14516890</pub-id></mixed-citation></ref><ref id="pone.0178444.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Ikonomidis</surname><given-names>I</given-names></name>, <name><surname>Andreotti</surname><given-names>F</given-names></name>, <name><surname>Economou</surname><given-names>E</given-names></name>, <name><surname>Stefanadis</surname><given-names>C</given-names></name>, <name><surname>Toutouzas</surname><given-names>P</given-names></name>, <name><surname>Nihoyannopoulos</surname><given-names>P</given-names></name>. <article-title>Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin</article-title>. <source>Circulation</source>
<year>1999</year>;<volume>100</volume>:<fpage>793</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="pmid">10458713</pub-id></mixed-citation></ref><ref id="pone.0178444.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Goetzl</surname><given-names>EJ</given-names></name>, <name><surname>Goetzl</surname><given-names>L</given-names></name>, <name><surname>Karliner</surname><given-names>JS</given-names></name>, <name><surname>Tang</surname><given-names>N</given-names></name>, <name><surname>Pulliam</surname><given-names>L</given-names></name>. <article-title>Human plasma platelet-derived exosomes: effects of aspirin</article-title>. <source>FASEB J</source>
<year>2016</year>;<volume>30</volume>:<fpage>2058</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1096/fj.201500150R">10.1096/fj.201500150R</ext-link></comment>
<pub-id pub-id-type="pmid">26873936</pub-id></mixed-citation></ref></ref-list></back></article>